Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 4105615, 9 pages
http://dx.doi.org/10.1155/2016/4105615
Review Article

Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application

Kaichun Li1 and Jin Li1,2

1Tianyou Hospital, Tongji University, Shanghai 200331, China
2Fudan University Shanghai Cancer Center, Shanghai Medical College, Department of Medical Oncology, Shanghai 200032, China

Received 30 September 2015; Accepted 10 November 2015

Academic Editor: Ralf-Dieter Hofheinz

Copyright © 2016 Kaichun Li and Jin Li. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA—A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Chen, R. Zheng, H. Zeng, S. Zhang, and J. He, “Annual report on status of cancer in China,” Chinese Journal of Cancer Research, vol. 27, no. 1, pp. 2–12, 2011. View at Publisher · View at Google Scholar
  3. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, K. Oba, X. Paoletti et al., “Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis,” European Journal of Cancer, vol. 49, no. 7, pp. 1565–1577, 2013. View at Publisher · View at Google Scholar
  4. J. D. Croxtall and K. McKeage, “Trastuzumab: in HER2-positive metastatic gastric cancer,” Drugs, vol. 70, no. 17, pp. 2259–2267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Google Scholar
  6. L. Shen, J. M. Xu, F. Y. Feng et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport,” Zhonghua Zhong Liu Za Zhi, vol. 35, no. 4, pp. 295–300, 2013. View at Publisher · View at Google Scholar
  7. A. Sawaki, Y. Ohashi, Y. Omuro et al., “Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study,” Gastric Cancer, vol. 15, no. 3, pp. 313–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. H. Ryu, C. Yoo, J. G. Kim et al., “Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer,” European Journal of Cancer, vol. 51, no. 4, pp. 482–488, 2015. View at Publisher · View at Google Scholar
  9. Y. Kurokawa, N. Sugimoto, H. Miwa et al., “Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1),” British Journal of Cancer, vol. 110, no. 5, pp. 1163–1168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. A. Wainberg, A. Anghel, A. J. Desai et al., “Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo,” Clinical Cancer Research, vol. 16, no. 5, pp. 1509–1519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Hecht, Y. J. Bang, S. K. Qin et al., “Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiC Trial,” Journal of Clinical Oncology, vol. 31, no. 18, abstract LBA4001, 2013, ASCO Annual Meeting Proceedings ( Post Meeting Edition). View at Google Scholar
  12. T. Satoh, R.-H. Xu, H. C. Chung et al., “Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study,” Journal of Clinical Oncology, vol. 32, no. 19, pp. 2039–2049, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Lorenzen, J. R. Knorrenschild, G. Haag et al., “Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie,” European Journal of Cancer, vol. 51, no. 5, pp. 569–576, 2015. View at Publisher · View at Google Scholar
  14. J. Park do, N. J. Thomas, C. Yoon, and S. S. Yoon, “Vascular endothelial growth factor a inhibition in gastric cancer,” Gastric Cancer, vol. 18, no. 1, pp. 33–42, 2015. View at Publisher · View at Google Scholar
  15. A. Ohtsu, M. A. Shah, E. Van Cutsem et al., “Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study,” Journal of Clinical Oncology, vol. 29, no. 30, pp. 3968–3976, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Shen, J. Li, J. Xu et al., “Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study),” Gastric Cancer, vol. 18, no. 1, pp. 168–176, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Geng and J. Li, “Apatinib for the treatment of gastric cancer,” Expert Opinion on Pharmacotherapy, vol. 16, no. 1, pp. 117–122, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Li, S. Qin, J. Xu et al., “Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial,” Journal of Clinical Oncology, vol. 31, no. 26, pp. 3219–3225, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Qin, J. Li, J. Xu et al., “Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial,” Journal of Clinical Oncology, vol. 32, no. 5, supplement, abstract 4003, 2014. View at Google Scholar
  20. R. M. Poole and A. Vaidya, “Ramucirumab: first global approval,” Drugs, vol. 74, no. 9, pp. 1047–1058, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. C. S. Fuchs, J. Tomasek, C. J. Yong et al., “Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial,” The Lancet, vol. 383, no. 9911, pp. 31–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Wilke, K. Muro, E. Van Cutsem et al., “Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial,” The Lancet Oncology, vol. 15, no. 11, pp. 1224–1235, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. J. Casak, I. Fashoyin-Aje, S. J. Lemery et al., “FDA approval summary: ramucirumab for gastric cancer,” Clinical Cancer Research, vol. 21, no. 15, pp. 3372–3376, 2015. View at Google Scholar
  24. H. H. Yoon, J. C. Bendell, F. S. Braiteh et al., “Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial,” Journal of Clinical Oncology, vol. 32, article 5s, 2014. View at Google Scholar
  25. Y. Ling, Y. Yang, N. Lu et al., “Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells,” Biochemical and Biophysical Research Communications, vol. 361, no. 1, pp. 79–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Xu, N. Ma, F. Wang et al., “Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer,” OncoTargets and Therapy, vol. 6, pp. 925–929, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. G. D. Demetri, P. Reichardt, Y.-K. Kang et al., “Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial,” The Lancet, vol. 381, no. 9863, pp. 295–302, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Huynh, R. Ong, and D. Zopf, “Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer,” Journal of Experimental & Clinical Cancer Research, vol. 34, no. 1, article 132, 2015. View at Publisher · View at Google Scholar
  29. N. Pavlakis, K. M. Sjoquist, E. Tsobanis et al., “INTEGRATE: a randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC)-a study by the Australasian Gastrointestinal Trials Group (AGITG): final overall and subgroup results,” Annals of Oncology, vol. 26, supplement 4, Article ID iv119, 2015. View at Google Scholar
  30. A. Okines, D. Cunningham, and I. Chau, “Targeting the human EGFR family in esophagogastric cancer,” Nature Reviews Clinical Oncology, vol. 8, no. 8, pp. 492–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Lordick, Y.-K. Kang, H.-C. Chung et al., “Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 490–499, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Waddell, I. Chau, D. Cunningham et al., “Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 481–489, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. N. C. van Grieken, T. Aoyama, P. A. Chambers et al., “KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study,” British Journal of Cancer, vol. 108, no. 7, pp. 1495–1501, 2013. View at Publisher · View at Google Scholar
  34. T. Crombet-Ramos, J. Rak, R. Pérez, and A. Viloria-Petit, “Antiproliferative, antiangiogenic and proapoptotic activity of H-R3: a humanized anti-EGFR antibody,” International Journal of Cancer, vol. 101, no. 6, pp. 567–575, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Crombet, L. Torres, E. Neninger et al., “Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer,” Journal of Immunotherapy, vol. 26, no. 2, pp. 139–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Satoh, K. H. Lee, S. Y. Rha et al., “Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer,” Gastric Cancer, vol. 18, no. 4, pp. 824–832, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Du, Z. Zheng, S. Shi et al., “S-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer: a randomized, open-label phase 2 trial,” Medicine, vol. 94, no. 23, article e958, 2015. View at Publisher · View at Google Scholar
  38. S.-E. Al-Batran, M. Ducreux, and A. Ohtsu, “mTOR as a therapeutic target in patients with gastric cancer,” International Journal of Cancer, vol. 130, no. 3, pp. 491–496, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Doi, K. Muro, N. Boku et al., “Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer,” Journal of Clinical Oncology, vol. 28, no. 11, pp. 1904–1910, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Ohtsu, J. A. Ajani, Y.-X. Bai et al., “Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study,” Journal of Clinical Oncology, vol. 31, no. 31, pp. 3935–3943, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Dabney, R. Devine, N. Sein, and B. George, “New agents in renal cell carcinoma,” Targeted Oncology, vol. 9, no. 3, pp. 183–193, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. C. D. Hart, I. Migliaccio, L. Malorni, C. Guarducci, L. Biganzoli, and A. Di Leo, “Challenges in the management of advanced, ER-positive, HER2-negative breast cancer,” Nature Reviews Clinical Oncology, vol. 12, no. 9, pp. 541–552, 2015. View at Publisher · View at Google Scholar
  43. F. Lordick, “Targeting the HGF/MET pathway in gastric cancer,” The Lancet Oncology, vol. 15, no. 9, pp. 914–916, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Iveson, R. C. Donehower, I. Davidenko et al., “Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study,” The Lancet Oncology, vol. 15, no. 9, pp. 1007–1018, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Cunningham, N. C. Tebbutt, I. Davidenko et al., “Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study,” Journal of Clinical Oncology, vol. 33, supplement, abstract 4000, 2015. View at Google Scholar
  46. M. A. Shah, Y.-J. Bang, F. Lordick et al., “METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC),” Journal of Clinical Oncology, vol. 33, supplement, abstract 4012, 2015. View at Google Scholar
  47. Y. Kataoka, T. Mukohara, H. Tomioka et al., “Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks,” Investigational New Drugs, vol. 30, no. 4, pp. 1352–1360, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. M. A. Shah, Z. A. Wainberg, D. V. T. Catenacci et al., “Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer,” PLoS ONE, vol. 8, no. 3, Article ID e54014, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Elimova, R. Wadhwa, H. Shiozaki et al., “Molecular biomarkers in gastric cancer,” Journal of the National Comprehensive Cancer Network, vol. 13, no. 4, pp. e19–e29, 2015. View at Google Scholar